Legal & General Group Plc Acquires New Stake in Personalis, Inc. $PSNL

Legal & General Group Plc acquired a new stake in Personalis, Inc. (NASDAQ:PSNL) during the 2nd quarter, Holdings Channel reports. The institutional investor acquired 36,419 shares of the company’s stock, valued at approximately $488,000.

A number of other large investors also recently bought and sold shares of PSNL. Caitong International Asset Management Co. Ltd lifted its stake in shares of Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after acquiring an additional 1,479 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Personalis during the fourth quarter worth about $31,000. BNP Paribas Financial Markets raised its holdings in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares in the last quarter. Focus Partners Wealth purchased a new position in Personalis during the first quarter worth about $47,000. Finally, Quantbot Technologies LP purchased a new position in Personalis during the second quarter worth about $69,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Insider Activity at Personalis

In related news, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,558,668.88. This trade represents a 29.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction on Monday, June 29th. The stock was sold at an average price of $14.00, for a total value of $69,748.00. Following the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,783,662. This represents a 2.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 256,233 shares of company stock worth $3,568,236 in the last three months. Corporate insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

PSNL has been the topic of a number of analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Craig Hallum downgraded Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a research note on Monday, August 24th. BTIG Research raised their price target on Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a report on Monday, July 20th. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $14.54.

Personalis Stock Down 3.5%

Shares of NASDAQ PSNL opened at $16.60 on Wednesday. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -15.23 and a beta of 2.31. Personalis, Inc. has a 52 week low of $4.95 and a 52 week high of $18.89. The firm has a 50-day moving average price of $14.68 and a 200 day moving average price of $10.41.

Personalis (NASDAQ:PSNL) last issued its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%.The company had revenue of $22.36 million for the quarter, compared to analyst estimates of $16.69 million. Equities research analysts expect that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Personalis Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.